度普利尤单抗相关眼表疾病:BioDay登记前瞻性队列研究
该研究在荷兰乌得勒支大学医学中心纳入150例中重度特应性皮炎成人患者,在度普利尤单抗治疗基线、第4周和第28周进行眼科与皮肤科检查。结果显示基线时94.0%患者存在眼表疾病但仅60.0%报告眼部症状,28周内30.7%发生度普利尤单抗相关眼表疾病,结膜杯状细胞数量稳定但MUC5AC表达显著下降。
要点
- 基线眼表疾病患病率高达94.0%,但仅60.0%报告眼部症状,提示需主动筛查。
- 28周内30.7%患者发生度普利尤单抗相关眼表疾病,眼科用药使用率由15.3%升至64.7%。
- 结膜杯状细胞数量稳定但MUC5AC表达显著下降,提示黏蛋白功能受损。
核心结论
- 中重度特应性皮炎患者在使用度普利尤单抗前眼表疾病患病率已很高,治疗28周内30.7%发生度普利尤单抗相关眼表疾病,且结膜MUC5AC表达显著下降。
研究设计与样本
- 前瞻性单中心队列研究,纳入荷兰乌得勒支大学医学中心BioDay登记中接受度普利尤单抗治疗的中重度特应性皮炎成人患者,共150例。
- 在基线、第4周和第28周进行眼科与皮肤科检查,研究时间为2020年2月至2025年1月。
- 采用Utrecht眼表炎症与过敏疾病评分评估眼表疾病严重程度,并行结膜印迹细胞学检查杯状细胞数量与功能。
主要发现
- 基线时94.0%(141/150)患者存在眼表疾病,但仅60.0%(90/150)报告眼部症状。
- 28周度普利尤单抗治疗期间,30.7%(46/150)患者发生度普利尤单抗相关眼表疾病。
- 眼科药物使用率从基线15.3%(23/150)升至第28周64.7%(97/150)。
- 结膜杯状细胞数量在基线至第28周保持稳定,但Cytokeratin 19-CD45-MUC5AC+细胞的MUC5AC产生显著减少。
关键数值与推荐
- 度普利尤单抗相关眼表疾病定义为Utrecht眼表炎症与过敏疾病评分较基线增加≥3分。
- 基线眼表疾病患病率94.0%(n=141/150),眼部症状报告率60.0%(n=90/150)。
- 28周内度普利尤单抗相关眼表疾病发生率30.7%(n=46/150)。
- 眼科药物使用率基线15.3%(n=23/150),第28周64.7%(n=97/150)。
临床怎么用
- 对中重度特应性皮炎患者启动度普利尤单抗前应进行眼表评估,因基线眼表疾病患病率高达94.0%且多数无症状。
- 治疗期间应定期随访眼表,28周内约三成患者发生度普利尤单抗相关眼表疾病,且多数需增加眼科用药。
- 关注黏蛋白MUC5AC表达下降可能,即使杯状细胞数量稳定,眼表润滑功能仍可能受损。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dupilumab-associated ocular surface disease (DAOSD) is a frequently reported side effect in atopic dermatitis (AD) patients treated with dupilumab. This study aimed to investigate the frequency and severity of DAOSD, the effect of ophthalmic treatment on (DA)OSD, and the effect of dupilumab on conjunctival goblet cells (GCs). DESIGN: Prospective, monocenter cohort study PARTICIPANTS: Adult patients with moderate-to-severe AD from the BioDay registry treated with dupilumab at the University Medical Center Utrecht, the Netherlands. METHODS: Ophthalmological and dermatological examinations were performed at baseline (start of dupilumab), week 4, and week 28, between February 2020 and January 2025. Ocular surface disease (OSD) severity was assessed using the Utrecht Ophthalmic Inflammatory and Allergic Disease score. DAOSD was defined as a ≥3-point increase in Utrecht Ophthalmic Inflammatory and Allergic Disease score from baseline. Conjunctival impression cytology was performed to study the quantity and function of conjunctival GCs. MAIN OUTCOME MEASURES: Frequency and severity of DAOSD, and the quantity and function of conjunctival GCs during dupilumab treatment. RESULTS: OSD was present in 94.0% (n = 141/150) of AD patients at baseline, while only 60.0% (n = 90/150) reported ocular symptoms. During 28 weeks of dupilumab treatment, 30.7% (n = 46/150) of patients developed DAOSD. The use of ophthalmic medication increased from 15.3% (n = 23/150) at baseline to 64.7% (n = 97/150) at week 28. GC numbers remained stable between baseline and week 28, while Mucin 5AC (MUC5AC) production in Cytokeratin 19-CD45-MUC5AC+ cells significantly decreased. CONCLUSIONS: This study highlights the high prevalence of OSD in moderate-to-severe AD patients before dupilumab treatment. DAOSD was observed in 30.7% of patients, despite the increased use of ophthalmic treatment. While conjunctival GC numbers remain stable but low, dupilumab was associated with reduced MUC5AC expression.
引用
- Veldhuis N, Achten RE, van Luijk CM, et al. Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis: A Large Prospective Cohort Study From the BioDay Registry. Am J Ophthalmol. 2026. PMID: 42710730. doi:10.1016/j.ajo.2026.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。